Innovative Therapeutics Cour Pharmaceuticals is at the forefront of developing antigen-specific immune tolerance therapies for autoimmune diseases, offering a unique approach that aims to reprogram the immune system rather than suppress it, positioning them as a pioneer in disease-modifying treatments.

Expanding Portfolio The company is actively advancing treatments for a diverse range of autoimmune and inflammatory conditions including primary biliary cholangitis, type 1 diabetes, myasthenia gravis, and celiac disease, providing multiple avenues for partnership and commercialization opportunities.

Strong Industry Partnerships With collaborations involving major pharmaceutical giants such as Takeda, Ironwood, Roche, Pfizer, and Bristol Myers Squibb, Cour has established significant relationships that can facilitate co-development, licensing, and distribution channels.

Robust Funding & Growth Having successfully raised $105 million in funding, including a recent $5 million Series A round led by notable investors, Cour Pharmaceuticals demonstrates strong financial backing and a solid foundation for accelerating its pipeline and expanding market reach.

Leadership & Vision The appointment of industry veteran Tim Walbert as CEO and the addition of a skilled Chief Medical Officer reinforce the company's strategic growth plan, making it an attractive partner for stakeholders interested in innovative biotech developments.